Ex-Woodford holdings continue to knock Schroders trust as NAV plunges 20% portfolio-adviser.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from portfolio-adviser.com Daily Mail and Mail on Sunday newspapers.
Former Woodford holding sees gains boosted by Oxford Nanopore success
DNA sequencing start-up among bundle of stocks sold to Acacia Research in June last year
Former Neil Woodford stock IP Group has announced its first ever dividend after a boost from underlying portfolio company Oxford Nanopore.
Analysts at Jefferies noted IP Group’s portfolio gains during 2020 of £225m were well ahead of its forecast. The largest difference, it said, was an increase in the fair value of the Oxford Nanopore stake of £77m. This meant NAV was £155m, or 14p a share above forecast.
Jeffries said IP Group’s 15% holding in Oxford Nanopore is now valued at £340m as the company itself is worth £2.3bn.
The UK needs patient capital but Neil Woodford is not the man to deliver it portfolio-adviser.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from portfolio-adviser.com Daily Mail and Mail on Sunday newspapers.
Richard Gaunt wants to increase his income yield from 3pc to 6pc
Credit: JAY WILLIAMS
A steady income in retirement is the holy grail for most investors. Richard Gaunt, 74, from Somerset, is no different.
The semi-retired public relations professional has several moving parts to his savings plan. First, there is his £300,000 Isa used to supplement pension income. However, he wants more and needs to boost the yield from 3pc to 6pc, while making sure it doesn’t dwindle in size.
“My aim is to improve my income and ensure my wife has enough to live on when I am gone. I want to keep my total funds above a safety net of £400,000,” he said.
Immunocore Prices NASDAQ IPO The Company (LSE: SUPP) is pleased to announce that its portfolio company Immunocore Holdings plc ( Immunocore ) has announced the pricing of its initial public offering ( IPO ) of 9,935,896 American Depositary Shares ( ADSs ) representing 9,935,896 ordinary shares at an IPO price of $26.00 per ADS, for total gross proceeds of approximately $258.3 million. Immunocore also raised $15 million in a concurrent private placement. Immunocore s ADSs are expected to begin trading on The Nasdaq Global Select Market ( NASDAQ ) on February 5, 2021 under the ticker symbol IMCR. In addition, Immunocore has granted the underwriters a 30-day option to purchase up to an additional 1,490,384 ADSs at the initial public offering price, less underwriting discounts and commissions.